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Factor (F)VIII N8-GP, turoctocog alfa pegol, is a 40-kDa glycopegylated version of the B domain truncated recombinant FVIII Novoeight (N8;
Novo Nordisk). Variability in the predicted and measured factor level of N8-GP between one-stage clotting assay (OSA) and chromogenic factor VIII assay, and between various OSA depending on activated partial thromboplastin time (aPTT) reagents, notably those with silica-based activators has been observed. 1, 2 In Research and Practice in Thrombosis and Haemostasis, Persson and colleagues investigated the mechanisms underlying these differences. 3 By measuring FXIa generated on contact activation, measuring activation of N8-GP by thrombin and measuring FXa generation in the presence of various OSA aPTT reagents, the authors showed that the variable results are, at least in part, the result of the differing times of contact activation within each assay. Longer incubation times for contact activation in the OSA resulted in relatively higher levels of FXIa accumulation. This, together with an overall slower rate of activation of N8-GP by endogenous thrombin formed in the OSA, resulted in underestimation of the N8-GP level. Interestingly, shortening the contact activation time diminished the underestimation in reagents associated with a discrepancy, whereas prolonging the time resulted in underestimation in OSA previously not associated with a discrepancy. The underestimation was not the result of silica based activators per se, but a variability in assay conditions. The study highlights the problems involved in ensuring accurate measurement of enhanced half-life (EHL) product treatment where even modest differences in assays reaction conditions can give rise to apparently discrepant assay results. The 60-kDa PEG moiety prolongs silica-based clotting time but is not affected by ellagic acid-based aPTT reagents. 7 In contrast, certain silica-based FIX OSA greatly overestimate the FIX level of the N-glycopegylated FIX product, N9-GP. Rosen and colleagues elegantly showed that this was due to N9-GP adsorption to the silica particles and subsequent enhanced activation of N9-GP, even in the absence of Ca 2+ ions. This enhanced activation resulted in a shortening of clotting times and gross overestimation of N9-GP levels. 8 To further complicate matters, the effects are not seen in all silica-based aPTT reagents. Indeed, in this study of N8-GP Persson and colleagues show that although N8-GP has a similar 40-kDa covalently linked glycopegylated moiety as N9-GP, there was no additional adsorption of N8-GP to silica particles compared to the unmodified FVIII product, and it was solely the length of contact activation together with the level of thrombin cleavage that affected the relative FVIII recovery levels. 3 Furthermore, OSA discrepancies are not limited to pegylated EHL products.
Studies using a variety of OSA reagents showed that when measuring the recombinant FIX Fc fusion protein Alprolix (Bioverativ Therapeutics Inc, Waltham, MA, USA), kaolin based activators underestimated recovered levels by ~50%. The aim of measuring treatment levels is to monitor the behavior of the prescribed EHL dose in a patient and ensure appropriate treatment.
The prescribed dose is based on, and calculated using, the labelled potency. The "true" value of an EHL product therefore is best estimated by the same method that was used to assign potency. The exact reagents and conditions used by manufacturers in potency assignment are rarely detailed. As described above, FVIII product potency in Europe is assigned using a chromogenic assay, though this is not necessarily the situation in the USA. Although the preferred method for monitoring FVIII treatment is the OSA, knowledge of the method used to assign potency, including details of reagents would be valuable. This is especially the case for FIX EHL products where both potency and monitoring are generally, though not exclusively, performed by OSA.
Assay discrepancies present problems for clinical teams and laboratories, nonetheless, by further investigating underlying assays differences in EHL concentrate measurement, Persson and colleagues not only give insight to those mechanisms, but also further illuminate the biological science of the assays themselves.
